🔴 Lipocine is trading 5.1% down today with no clear catalyst identified

Lipocine is trading 5.1% down at $2.12, with no clearly attributable company-specific catalyst identified for September 22, 2026.

• The latest company announcement was the September 14 initiation of its BLOOM Phase 3 study.
• H.C. Wainwright reiterated a Neutral rating and $4.00 price target on September 22; those developments do not directly explain today’s decline.
• Biotech is rising, so sector strength does not explain the stock’s opposite-direction move.